|
09.06.2014 18:26:00
|
Merck & Co., Inc. -- Moody's: Merck's Idenix acquisition is credit negative
New York, June 09, 2014 -- Moody's Investors Service commented that the acquisition of Idenix Pharmaceuticals, Inc. (unrated) by Merck and Co., Inc. ("Merck") for $3.85 billion is credit negative. However, there is no effect on Merck's current ratings including the A1 senior unsecured long-term rating (on guaranteed obligations), the A2 senior unsecured long-term rating (on non-guaranteed obligations) and the Prime-1 short-term rating. The rating outlook is stable.
Letzte Top-Ranking Nachrichten
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.